Objective-To investigate the risk of enzyme sensitisation and clinical allergy in workers exposed to enzymes at Novo Nordisk A/S. Methods-The study was a retrospective follow up study based on medical history and test data originally collected at routine screenings for enzyme allergy by the Occupational Health Service (OHS) of Novo Nordisk AMS during the period 1970-92. Workers were exposed to proteases, lipases, cellulases, and carboxyhydrases. Medical records of 3815 subjects were registered in the OHS database. According to criteria including possible enzyme exposure, allergy tests at the time of engagement, and participation in the allergy screening programme 1064 were selected for the present study. Outcomes were allergy symptoms, specific IgE test (radioallergosorbent test (RAST)) to enzymes, skin test reactions to common allergens and enzymes, forced expiratory volume in one second (FEV,), and forced vital capacity (FVC). Potential risk factors were smoking habits, workplace, type of job, age, and sex. Results-Sensitisation occurred to all types of enzymes handled in the plant, most often in production areas and laboratories; 8.8% developed clinical enzyme allergy during the first three years of employment. The risk declined during the period. The frequency of enzyme sensitisation, expressed as RAST values > 0.5 SU, was 36%, and the frequency of significant RAST values > 2 SU was 8%. Ranking diagnoses of enzyme allergy by severity, the frequency ofasthma was 5.3%, rhinitis 3.0%, and urticaria 0.6%. Half of the cases occurred within the first 15 months of exposure. Smoking was an independent risk factor for clinical enzyme allergy (odds ratio (OR)=2.3 (95% exact confidence interval (95% CI) 1.4 to 3.9), measurable RAST ¢0.5 SU (OR=1.5 (95% CI 1.1 to 2.1)), and RAST 2 SU (OR=4.5 (95% CI 2.2 to 8.4)). Atopic predisposition at the time of engagement was not a significant risk factor for enzyme allergy. This could be due to various selection mechanisms.
Novo Nordisk A/S has produced detergent enzymes since 1962, and later on also other types of industrial enzymes. Clinical enzyme allergy and enzyme sensitisation in employees exposed occupationally to enzymes is well known.' -6 Previous publications gave results on allergy frequencies to selected proteases (alcalase and esperase).6 In this study we evaluated the risk at Novo Nordisk A/S to a wider variety of enzymes.
Since 1974, all applicants to jobs in departments handling enzymes were counselled about the allergy risk, offered the opportunity to participate in the health surveillance programme, and tested for atopy6 7 with a skin test panel of common northern European allergens. Pepys' definition of atopy as a positive skin test reaction was used.8 9 Up to 1980, a positive skin test excluded applicants from employment in jobs with exposure to enzymes. Since 1980 jobs have been classified by assumed risk and atopic subjects were from then on engaged in departments with lower exposure (for example, laboratories). From February 1987, the pre-employment tests have served solely as a background for counselling the applicants. Departments were included in the allergy screening programme when enzyme sensitisation had occurred "recently", or if evaluations of exposure and working conditions indicated a high risk of sensitisation. The health surveillance programme included a test for specific IgE antibodies (radioallergosorbent test; RAST), information about exposure to enzymes, medical history, and clinical tests, including lung function and, in some cases, skin tests. The screening intervals varied, but were typically once or twice yearly.
The study comprised: (1) evaluation of medical records and registration of the data in a database; (2) 3 Values for RAST (in Sorbent Units (SU)) are given at three levels: <0.5 (below the detection limit), 0. 15 At the time of the employment 57% were smokers and 41 % non-smokers, and for 2% no information on smoking habits could be found.
FOLLOW UP
The population During the three screening periods 69, 78, and 46 subjects respectively left the company leaving 871 persons followed up for at least 39 months.
DIAGNOSES
During the period 1970-92 a total of 94 (8.8%) people were diagnosed as having definite enzyme allergy and 27 (2.5%) were classified as suspected of having enzyme allergy (table 1) . These cases presented within the first 39 months after employment and the annual number ranged from 1 to 13. The incidence of enzyme allergy declined with time during the first 39 months of employment (0-15 months 52 (4.9%); 16-27 months 30 (2.8%); 28-39 months 12 (1.1%).
After 39 months of employment no systematic screening has been carried out. However, 23 (2.2%) additional cases of enzyme allergy from an exposed group of 871 were identified after more than 39 months of employment among workers consulting the OHS or in random surveys in certain departments. During 1970-92 the frequency of symptomatic allergy tended to decline. In 1970-79 the frequency was 10.3%, in 1980-86 9.5%, and in 1987-92 6.1% (P=0.07; Mantel-Haenszel test for trend).
RAST
Quantities and types of enzymes produced and the degree of exposure have varied with time, which is reflected in the number of RAST tests for each enzyme. Table 2 shows the results of RAST analyses of the most important enzymes.
Most RAST analyses were made in connection with scheduled screenings. Three hundred and fifty five (36%) subjects of 995 tested at follow up had a RAST value above the detection limit of 0.5 SU and 76 (8%) 2 SU for one or more enzymes (table 3) .
Occurrence of enzyme allergy and RAST correlated well: 52 (68%) with RAST > 2.0 SU had allergy symptoms; 11 (1.7%) with negative RAST were diagnosed as having allergy to enzyme (table 3) .
However, of those with RAST ¢2.0 SU, eight (10.5%) had no diagnosis of symptomatic allergy. Of subjects with RAST between 0.5 and 2.0 SU 240 (86%) had no enzyme allergy.
LUNG FUNCTION
Outcome of lung function tests during the screening periods were compared with corre- There was no tendency for an association between age or sex and enzyme allergy. This is remarkable, most male workers being employed in production areas in which the exposure levels were highest but also with the greatest selection. The risk of symptomatic allergy was significantly increased in smokers compared with non-smokers (11% v 5%, odds ratio (OR) 2.3 (95% exact confidence interval (95% CI) 1.4 to 3.9)).
Sensitisation to enzymes, expressed as increasing RAST value in SU, was significantly increased in smokers compared with non-smokers (RAST value 0.5-<2 SU: 29% v 23%, OR 1.5 (95% CI 1.1 to 2.1) and RAST value 32 SU: 10% v 3%, OR 4.5 (95% CI 2.2 to 8.4)).
A positive skin test at the pre-employment examination did not predispose to clinical enzyme allergy (OR 1.0 (95% CI 0.45 to 2.0)).
Likewise, clinical allergy at the preemployment examination did not predispose to enzyme allergy or sensitisation (tables 4 (25) 67 (7) 62 (7) Sum 640 (60) 279 (26) 76 (7) 69 (7) Values in parentheses are % across rows. and an open access to health check in the OHS. Likewise, replacement to non-exposure workplaces is offered to enzyme allergic employees and salary compensation from insurance given. The surveillance programme does not include an exit examination and therefore some employees may have left with an unidentified enzyme allergy. The recruitment practices and the occasional intervention by replacement of persons with raised RAST values irrespective of symptoms may both add to an underestimation of the risk. In previous studies6 7 lower frequencies of enzyme allergies were found. These studies, however, only included two selected Bacillus subtilis enzymes. For those enzymes (Alcalase and Esperase) frequencies of RAST >2.0 SU were similar to the 3% found in our study.
Scratch tests were usually carried out for rapid diagnosis of enzyme allergy or as a supplement to low RAST values. The subjects were usually tested with a full enzyme panel, disregarding actual exposure history. A higher proportion of positive skin tests than RAST was found with up to 25% positive reactions for some allergens. The rationale for testing with RAST or scratch tests means that the tests are incomparable in respect of sensitivity or for assessment of the relative allergenicity of enzymes. Cross reactions between enzymes occur, and must be taken into consideration.
Some studies report the risk of enzyme allergy in industries using enzymes,2 3 16 " especially in production of detergents with enzymes added. From these studies prevalences of 17%-21 % for positive skin tests were found 4-24.1 %) . This prevalence includes subjects not employed and therefore excluded from the database. It is higher than that found in the study group and somewhat lower than expected in a population of Danish adults (prevalences 21%-28%).'4 ' The differences may be a result of selection in the recruitment procedure before the pre-employment test and after the examination. A selection may also have taken place before application for a job, as the allergy risk associated with the company may be known in the community.
Among the atopic subjects we did not see the expected excess risk for enzyme sensitisation. However, only the "mildest" cases were engaged (for example, low asthma frequency among applicants) and they were probably employed in departments with the lowest exposure and followed up by more rigorous medical surveillance. Further, as a secondary preventive measure, atopic subjects with increased RAST may have been moved more readily and earlier to non-exposed jobs, than non-atopic subjects. These factors will mask a correlation between atopy and subsequent enzyme allergy. However, we cannot confirm that atopy is a definite factor for enzyme allergy. Future studies of populations less selected will, therefore, be more valid regarding the importance of allergic predisposition. The results do not justify rigorous selection on the basis of pre-employement examination.
Smoking was an unequivocal risk factor of allergy. Smoking was not a criteria for selection, but the risk from smoking should be included in future counselling. The explanation of the negative correlation between smoking and atopy at engagement may be that atopic smokers were selected out on account of several symptoms. The impact of smoking on production of specific IgE antibody and as a risk factor in occupational disease still needs further study.2 As mentioned, decline in lung function tests overall correlated well with smoking habits and to development of allergy among smokers. However, this does not imply that this test can be considered to be suitable for screening for allergy. Rather, single lung function tests reflect the gravity and nature of lung disease.
No published studies consider the risk of enzyme allergy in relation to threshold limit values (TLVs) (TLV for proteases= 0.06 ,ug/m').2' The TLV was originally set as a recommendation in the late 1960s and early 1970s. '6 19 28 29 The obtainable exposure concentration in the production of detergents with granulated subtilisin, rather than scientific results, seems to have been the guiding factor for the TLV. The general dust concentrations have decreased over the period of 20 years covered by this study. In laboratory areas dust concentrations, characterized by 50 and 90% percentiles, have ranged between 0.05 and 0.1 jig/m' (maximum 0.8 jg/m' enzyme protein).
In production areas handling enzyme powder, dust concentrations of about 0.1-1.0 jg/m' have been measured (maximum 2 ig/im'). Face masks were prescribed at enzyme concentrations above 0.6 jig/m'.
The National Research Council's Ad Hoc Committee stated in 1971 that despite a great number of consumers, only six cases of definite IgE induced allergy to enzyme detergents were found in consumers tested.26 30 Since the introduction of granulated enzymes no cases of sensitisation or allergic respiratory disease in consumers have been reported.
Despite increased quantities produced, the number of cases of enzyme allergy at Novo Nordisk A/S seems to have decreased over the period of investigation, probably due to improved industrial hygiene and training. However, 8.8% still developed allergy, half of them with lung symptoms.
